# A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma

> **NCT01271803** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 131 (actual)

## Conditions studied

- Malignant Melanoma

## Interventions

- **DRUG:** Cobimetinib
- **DRUG:** vemurafenib

## Key facts

- **NCT ID:** NCT01271803
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02-17
- **Primary completion:** 2013-10-01
- **Final completion:** 2017-12-12
- **Target enrollment:** 131 (ACTUAL)
- **Last updated:** 2019-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01271803

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01271803, "A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01271803. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*